On February 9, 2017, KEI filed written comments to the Office of the United States Trade Representative’s Special 301 Review process.
The Special 301 Review is an annual process carried out by the USTR to, “to identify countries that deny adequate and effective protection of intellectual property rights (IPR) or deny fair and equitable market access to U.S. persons who rely on intellectual property protection.”
On Monday morning, 17 October 2016, the United States Trade Representative, Michael Froman, delivered a lecture at the Graduate Institute entitled, The WTO in a Time of Change: Some Reflections.
Members of the World Trade Organization (WTO) meet this week in Geneva (15 October 2015 – 16 October 2015) to decide if the poorest countries on earth are exempt from WTO rules for pharmaceutical patents. The WTO’s TRIPS Council is expected to make a decision in respect of the request of the LDC Group’s request for indefinite exemption from TRIPS obligations on pharmaceutical patents. Continue Reading
On 16 December 2014 and 18 December 2014, the World Trade Organization (WTO) undertook a trade policy review of the United States of America. All members of the WTO are subject to review under the Trade Policy Review Mechanism (TPRM). Continue Reading
Previously, KEI reported on the terms of reference (TOR) for the confidentiality of the Transatlantic Trade and Investment Partnership (TTIP) negotiating texts, as laid out in a letter by USTR to DG-Trade. Although evidently publicly available, the EU counterpart of that letter was not accessible through the FOIA process. Obtained through the EU Regulation (EC) No. Continue Reading
KEI has obtained the terms of reference (TOR) for the confidentiality of the negotiating texts of the Transatlantic Trade and Investment Partnership (TTIP) Agreement. The TOR are laid out in a two-page letter from US Chief Negotiator Dan Mullaney to EU Chief Negotiator Ignacio Garcia-Bercero which is available here. The letter was obtained through a FOIA request filed by KEI with the USTR on May 19, 2014.
Wednesday, at the George Mason University Law Campus in Arlington, VA, the Office of the US Trade Representative hosted an all day Stakeholder Forum in conjunction with the fifth negotiating round of the Transatlantic Trade and Investment Partnership. The first part of the day was devoted to Stakeholder Policy Presentations, with several hours of presentations by a variety of industry, academics, trade associations, and public interest groups. The latter part of the day consisted of a briefing by the US Chief Negotiator Dan Mullaney and the EU Chief Negotiator Ignacio Garcia-Bercero.
Comments of KEI, regarding USTR Request For Comments From The Public On The Creation Of The Public Interest Trade Advisory Committee And Request For Nominees To That Committee.
Submitted to Regulations.gov on March 25, 2014, under docket number USTR-2014-0005.
Intellectual property issues are an important element of US trade agreements, and according to a recent study by Open Secrets, the most intensively lobbied issue, by far.
Among the comments that KEI filed today in the 2014 Special 301 Review process were comments regarding pharmaceutical companies’ donation and patient assistance programs. An oft-cited claim by pharmaceutical companies and those lobbying on their behalf is that donations and patient assistance programs fully provide for those that cannot afford the high priced medications offered by the companies. Continue Reading
On Saturday, August 3, 2013, USTR head Ambassador Michael B. G. Froman wrote to the Chairman of the U.S. International Trade Commission (ITC), to “disapprove the USITC’s determination to issue an exclusion order and cease and desist order” for Apple Inc. “smart phones and tablet computers that infringe a U.S. patent owned by Samsung Electronics,” in the ITC Investigation No. 337-TA-794. Continue Reading